Cargando…

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study

This study aimed to compare adalimumab originator vs. biosimilar in HS patients, and to evaluate the effect of a switch to a biosimilar, or a switch back to the originator, in terms of treatment ineffectiveness. Patients with a diagnosis of HS were enrolled from 14 Italian sites. Treatment ineffecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burlando, Martina, Fabbrocini, Gabriella, Marasca, Claudio, Dapavo, Paolo, Chiricozzi, Andrea, Malvaso, Dalma, Dini, Valentina, Campanati, Anna, Offidani, Annamaria, Dattola, Annunziata, Caro, Raffaele Dante Caposiena, Bianchi, Luca, Venturini, Marina, Gisondi, Paolo, Guarneri, Claudio, Malara, Giovanna, Trifirò, Caterina, Malagoli, Piergiorigio, Fargnoli, Maria Concetta, Piaserico, Stefano, Carmisciano, Luca, Castelli, Riccardo, Parodi, Aurora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599334/ https://www.ncbi.nlm.nih.gov/pubmed/36289787 http://dx.doi.org/10.3390/biomedicines10102522

Ejemplares similares

Hidradenitis suppurativa and adalimumab in the COVID-19 era
por: Marzano, Angelo Valerio, et al.
Publicado: (2021)

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study
por: Pellegrini, Cristina, et al.
Publicado: (2022)

IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa
por: Malvaso, Dalma, et al.
Publicado: (2023)

Hair removal and deodorants in hidradenitis suppurativa: An online survey on patients' habits
por: Lauro, Wanda, et al.
Publicado: (2022)

Secukinumab and hidradenitis suppurativa: Friends or foes?
por: Marasca, Claudio, et al.
Publicado: (2019)

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
por: Gisondi, Paolo, et al.
Publicado: (2021)

Hidradenitis suppurativa flares following COVID-19 vaccination: A case series
por: Martora, Fabrizio, et al.
Publicado: (2022)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Teledermatology in the management of hidradenitis suppurativa: Should we improve this service?
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis
por: Scala, Emanuele, et al.
Publicado: (2020)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
por: Martora, Fabrizio, et al.
Publicado: (2023)

Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience
por: CHIRICOZZI, Andrea, et al.
Publicado: (2020)

Hidradenitis suppurativa and psoriasis: the odd couple
por: Macca, Laura, et al.
Publicado: (2023)

Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
por: Bellinato, Francesco, et al.
Publicado: (2022)

Creation of a severity index for hidradenitis suppurativa that includes a validated quality‐of‐life measure: the HIDRAscore
por: Marzano, A.V., et al.
Publicado: (2020)

Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis
por: Malara, Giovanna, et al.
Publicado: (2021)

Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience
por: Gisondi, Paolo, et al.
Publicado: (2021)

Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021)

Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study
por: TALAMONTI, Marina, et al.
Publicado: (2021)

Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report
por: Ruggiero, Angelo, et al.
Publicado: (2023)

A Dermatological Questionnaire for General Practitioners with a Focus on Hidradenitis Suppurativa
por: Marasca, Claudio, et al.
Publicado: (2018)

How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study
por: Giofrè, Claudia, et al.
Publicado: (2023)

Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature
por: Garcovich, Simone, et al.
Publicado: (2020)

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs
por: Burzi, Lorenza, et al.
Publicado: (2022)

Role of Nutrition and Adherence to the Mediterranean Diet in the Multidisciplinary Approach of Hidradenitis Suppurativa: Evaluation of Nutritional Status and Its Association with Severity of Disease
por: Barrea, Luigi, et al.
Publicado: (2018)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
por: REPETTO, Federica, et al.
Publicado: (2022)

The CANOVA Study Real-World Evidence of Biologic Treatments in Moderate-Severe Psoriasis in Italy: A Gender Perspective
por: Colombo, Delia, et al.
Publicado: (2022)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
por: Talamonti, Marina, et al.
Publicado: (2023)

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
por: REPETTO, Federica, et al.
Publicado: (2023)

Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus
por: Damiani, Giovanni, et al.
Publicado: (2023)

Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study
por: COSTANZO, Antonio, et al.
Publicado: (2021)

Intralesional Diode Laser 1064 nm for the Treatment of Hidradenitis Suppurativa: A Report of Twenty Patients
por: Fabbrocini, Gabriella, et al.
Publicado: (2018)

Prevalence of Neuropathic Pain and Related Characteristics in Hidradenitis Suppurativa: A Cross-Sectional Study
por: Garcovich, Simone, et al.
Publicado: (2020)

Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa
por: Fania, Luca, et al.
Publicado: (2022)

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Hidradenitis Suppurativa in Patients with HIV: A Scoping Review
por: Macca, Laura, et al.
Publicado: (2022)

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
por: GNESOTTO, Laura, et al.
Publicado: (2023)

Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic
por: Esposito, Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cgomfjuji70b5bbe7klooqt5te